Sino Biopharmaceutical
VC Fund
Wan Chai, Hong Kong
Sino Biopharmaceutical is a VC fund in Wan Chai focused on Biotechnology and Health Care. Sino Biopharmaceutical engages in pharmaceutical products which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemicalmedicines for treating tumours, liver diseases, cardio-cerebral diseases, analgesia, respiratory system diseases and orthopedicdiseases.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Sino Biopharmaceutical invests in
Stages Sino Biopharmaceutical invests in
Countries Sino Biopharmaceutical invests in
Round sizes
Contacts
Round size
- Series B
- $91M–$110M
- Series C
- $42M–$736M
- Series D
- $27M–$400M
Investment Focus
Industry
- Biotechnology 9 (56%)
- Health Care 7 (44%)
- Medical 6 (38%)
- Biopharma 5 (31%)
- Manufacturing 4 (25%)
Stage
- Series B 3 (19%)
- Series D 3 (19%)
- Series C 2 (13%)
- Venture - Series Unknown 2 (13%)
- Seed 1 (6%)
Country
- China 10 (63%)
- United States 3 (19%)
- Israel 1 (6%)
- Taiwan 1 (6%)
- Singapore 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Hsin Tse
Executive Director and VP
|
Executive Director and VP | Total investments: 2 | Find email | |
|
Ping Tse
Founder & Sr. Vice Chairman
|
Founder & Sr. Vice Chairman | Total investments: 0 | Find email | |
Yi Li
President & CEO
|
President & CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Hongxin Biology
|
Hongxin Bio is an mRNA drug developer, focusing on nucleic acid drug delivery and RNA drug development. | Series B / Aug 13, 2026 | |
TranscEngram
|
TranscEngram is an AI research and technology company focused on advancing artificial intelligence. | Angel / Jul 05, 2026 | |
AI² Robotics
|
AI² Robotics is an embodied intelligent robot company that offers research and development of general intelligent embodied terminals. | $735.9M / Series C / Jun 29, 2026 | |
|
Sanegene Bio
|
Sanegene Bio is currently operating in stealth mode. | $110M / Series B / Dec 08, 2025 | |
Phrontline Biopharma
|
Phrontline Biopharma specializes in the development of ADC to address unmet medical needs in the field of oncology. | $60M / Seed / Nov 21, 2025 | |
|
PaiLin Biotech
|
PaiLin Biotech is a specialized blood product provider focused on the production, collection, storage, and sales of high-quality single-donor plasma. | $534.4M / Post-IPO Equity / Jun 11, 2025 | |
LaNova Medicines
|
LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs. | $42.2M / Series C / Oct 18, 2024 | |
HanchorBio
|
HanchorBio is a Biotechnology Research firm that is working to revolutionize the treatment of people with cancer. | $20M / Series A / Aug 25, 2022 | |
Generon (Shanghai) Corporation
|
Generon (Shanghai) Corporation Ltd. is an integrated biotech company developing therapeutic biologics for patients world-wide. Their research & development center is located in Zhang Jiang High-Tech Park, Shanghai, China. their cGMP drug manufacturing facility is located in Economic-Technological Development Area, Beijing, China. Theirmission is “Innovating for Life” to develop innovative therapeutic biologics for global patients with unmet medical needs. They employ their proprietary, cutting-edge technology platforms to discover, develop and manufacture biologic therapeutics. They are focused on “best-in-class” and “first-in-class” recombinant therapeutic proteins to treat cancer, autoimmune and inflammatory diseases. They follow international quality standards for their product development and adhere to regulatory requirements of the CFDA, FDA and EMA. “Innovation and quality” are the soul of Generon in the generation of scientific data and in the processes of drug discovery, development and manufacturing. | $70M / Venture - Series Unknown / Jun 02, 2022 | |
Evive Biotech
|
Evive Biotech develops biological therapies for oncology and inflammatory disorders. The company uses proprietary technology platforms to advance drug candidates. It also manages drug development, regulatory compliance, and commercial-scale manufacturing for biologics. | $70M / Venture - Series Unknown / Jun 02, 2022 | |
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Sino Biopharmaceutical invest in?
Sino Biopharmaceutical invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series D stage. Most of the 16 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Sino Biopharmaceutical's check size?
Sino Biopharmaceutical typically joins rounds of $91M–$110M at Series B, $42M–$736M at Series C and $27M–$400M at Series D. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sino Biopharmaceutical participates in.
How do I contact Sino Biopharmaceutical?
Public channels for Sino Biopharmaceutical include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sino Biopharmaceutical?
The team at Sino Biopharmaceutical includes Hsin Tse (Executive Director and VP), Ping Tse (Founder & Sr. Vice Chairman) and Yi Li (President & CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
